LataMed AI and Droguerías Lala Partner to Develop AI Tools for Pharmaceutical and Laboratory Workflows

LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced a new agreement with Droguerías Lala C.A., a Venezuelan pharmaceutical distributor, to develop AI-supported and automated software tools for pharmaceutical and laboratory workflows. The collaboration, conducted through LataMed's Venezuelan subsidiary LATAMEDAI VE, aims to design, develop, test, and evaluate customized technology to support processes such as pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis.

The proposed technology is expected to include software tools that organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionalities may encompass workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytics to help qualified personnel identify potential inconsistencies or operational issues earlier. The companies will begin by identifying specific workflows, defining technical and operational requirements, and establishing a phased development and testing process, along with confidentiality, information-security, data-management, and access-control procedures.

The initiative is significant because it represents a strategic move by LataMed AI to expand beyond its patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. According to Dr. Kevin Rodan Levy, CEO of LataMed AI, “This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments.” He emphasized that the technology is designed to support data analysis, documentation, testing coordination, and quality control while preserving professional oversight.

Importantly, the technology will not independently approve pharmaceutical formulas, laboratory results, or regulatory submissions. All scientific and regulatory decisions will remain the responsibility of qualified professionals and authorities. The collaboration aligns with LataMed's broader strategy to develop digital infrastructure and AI tools for healthcare providers, pharmacies, laboratories, and institutions across Latin America. If successful, the technology could be adapted for other organizations in Venezuela and the region, subject to separate agreements and regulatory requirements.

The agreement establishes a framework for development but does not guarantee implementation timelines, commercial deployment, cost reductions, or revenue. Intellectual property ownership and commercialization terms will be defined in the agreement and additional documentation. The potential impact of this partnership is substantial, as it could lead to more efficient pharmaceutical research and quality control processes, ultimately improving patient safety and operational effectiveness in Latin American healthcare systems.

LataMed AI is also developing AI-supported platforms like CardioAI, PulmoAI, and NeuroAI for cardiovascular, pulmonary, and neurological health information evaluation. These platforms remain under development and subject to regulatory approval. The company's focus on leveraging AI to enhance healthcare delivery and operational efficiency positions it at the forefront of digital health innovation in the region.